LOGIN  |  REGISTER
Recursion
Astria Therapeutics

RadNet to Present at the Sidoti & Company Fall 2023 Virtual Conference on Wednesday, September 20th

September 20, 2023 | Last Trade: US$72.70 1.32 1.85

LOS ANGELES, Sept. 20, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Fall 2023 Conference on Wednesday, September 20th at 4:00 p.m. Eastern Time.

There will be simultaneous and archived webcasts available at https://sidoti.zoom.us/webinar/register/WN_1qNfmm8xQX6AHwKesZ3aJw
and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:

Date:Wednesday, September 20, 2023
Time:4:00 p.m. Eastern Time
URL:https://sidoti.zoom.us/webinar/register/WN_1qNfmm8xQX6AHwKesZ3aJw

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 363 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928

 


C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB